{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:18:21Z","timestamp":1790986701578,"version":"4.1.0"},"reference-count":49,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2005,6,13]],"date-time":"2005-06-13T00:00:00Z","timestamp":1118620800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>A recombinant bispecific single\u2010chain fragment variable antibody (bsscFv), directed against the B\u2010cell antigen CD19 and the low affinity Fc\u2010receptor Fc<jats:italic>\u03b3<\/jats:italic>RIII (CD16), was designed for use in the treatment of patients with leukaemias and lymphomas. The Fc\u2010portions of whole antibodies were deliberately eliminated in this construct to avoid undesired effector functions. A stabilised bsscFv, ds[CD19\u2003\u00d7\u2003CD16], was generated, in which disulphide bonds bridging the respective variable light (VL) and variable heavy (VH) chains were introduced into both component single\u2010chain (sc)Fvs. After production in 293T cells and chromatographic purification, ds[CD19\u2003\u00d7\u2003CD16] specifically and simultaneously bound both antigens. The serum stability of ds[CD19\u2003\u00d7\u2003CD16] was increased more than threefold when compared with the unstabilised counterpart, while other biological properties were not affected by these mutations. In antibody\u2010dependent cellular cytotoxicity experiments, ds[CD19\u2003\u00d7\u2003CD16] mediated specific lysis of both CD19\u2010positive malignant human B\u2010lymphoid cell lines and primary tumour cells from patients with B\u2010cell chronic lymphocytic leukaemia or B\u2010cell acute lymphoblastic leukaemia. Natural killer cells, mononuclear cells (MNCs) from healthy donors and, in some instances, MNCs isolated from patients after allogeneic stem cell transplantation, were used as effectors. Thus, ds[CD19\u2003\u00d7\u2003CD16] holds promise for the treatment of CD19<jats:sup>+<\/jats:sup> B\u2010lineage malignancies.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2005.05414.x","type":"journal-article","created":{"date-parts":[[2005,7,6]],"date-time":"2005-07-06T23:25:42Z","timestamp":1120692342000},"page":"218-228","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Effective lysis of lymphoma cells with a stabilised bispecific single\u2010chain Fv antibody against CD19 and Fc<i>\u03b3<\/i>RIII (CD16)"],"prefix":"10.1111","volume":"130","author":[{"given":"Joerg","family":"Bruenke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Barbin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Kunert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Stieglmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich","family":"Niethammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Stockmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Peipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Repp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Valerius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg H.","family":"Fey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,6,13]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(96)00227-X"},{"key":"e_1_2_6_3_1","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood.V82.6.1803.1803","article-title":"Lysis of malignant B cells from patients with B\u2010chronic lymphocytic leukemia by autologous T cells activated with CD3\u2003\u00d7\u2003CD19 bispecific antibodies in combination with bivalent CD28 antibodies","volume":"82","author":"Bohlen H.","year":"1993","journal-title":"Blood"},{"key":"e_1_2_6_4_1","first-page":"4310","article-title":"Cytolysis of leukemic B\u2010cells by T\u2010cells activated via two bispecific antibodies","volume":"53","author":"Bohlen H.","year":"1993","journal-title":"Cancer Research"},{"key":"e_1_2_6_5_1","first-page":"1704","article-title":"Prevention of Epstein\u2010Barr virus\u2010induced human B\u2010cell lymphoma in severe combined immunodeficient mice treated with CD3\u2003\u00d7\u2003CD19 bispecific antibodies, CD28 monospecific antibodies, and autologous T cells","volume":"57","author":"Bohlen H.","year":"1997","journal-title":"Cancer Research"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.16.7538"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.04893.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.754"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/74704"},{"key":"e_1_2_6_10_1","first-page":"1765","article-title":"Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3\u2003\u00d7\u2003CD19 bispecific antibody","volume":"10","author":"Csoka M.","year":"1996","journal-title":"Leukemia"},{"key":"e_1_2_6_11_1","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1182\/blood.V92.12.4750","article-title":"Immunotherapy of B\u2010cell lymphoma with CD3\u2003\u00d7\u200319 bispecific antibodies: costimulation via CD28 prevents \u2018\u2018veto\u2019\u2019 apoptosis of antibody\u2010targeted cytotoxic T cells","volume":"92","author":"Daniel P.T.","year":"1998","journal-title":"Blood"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/scd.1.1995.4.433"},{"key":"e_1_2_6_13_1","first-page":"67","article-title":"Bispecific antibody therapy of two murine B\u2010cell lymphomas","volume":"7","author":"Demanet C.","year":"1992","journal-title":"International Journal of Cancer. Supplement"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.9.3803.bloodjournal8793803"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02934.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.10.3275"},{"key":"e_1_2_6_17_1","first-page":"5713","article-title":"Antitumor effects of a bispecific antibody targeting CA19\u20139 antigen and CD16","volume":"52","author":"Garcia de Palazzo I.","year":"1992","journal-title":"Cancer Research"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050396"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V80.4.863.863"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509112195"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1992.tb05853.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1182\/blood.V84.2.556.556","article-title":"Killing of autologous B\u2010lineage malignancy using CD3\u2003\u00d7\u2003CD19 bispecific monoclonal antibody in end stage leukemia and lymphoma","volume":"84","author":"Haagen I.A.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3046.7.s3.7.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2042"},{"key":"e_1_2_6_25_1","first-page":"1873","article-title":"Anti\u2010CD16\/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines","volume":"7","author":"Hartmann F.","year":"2001","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01741331"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910550523"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19980831)77:5<763::AID-IJC16>3.0.CO;2-2"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.1.137"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.4971038.x"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703406"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1203"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1735"},{"key":"e_1_2_6_34_1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bcmd.2004.08.017","article-title":"Long\u2010term outcome after haploidentical stem cell transplantation in children","volume":"33","author":"Lang P.","journal-title":"Blood Cells, Molecules, and Diseases"},{"key":"e_1_2_6_35_1","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A recombinant bispecific single\u2010chain antibody, CD19\u2003\u00d7\u2003CD3, induces rapid and high lymphoma\u2010directed cytotoxicity by unstimulated T lymphocytes","volume":"95","author":"Loffler A.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(99)00057-7"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1089\/hyb.1984.3.305"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST0300507"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2003.12.001"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01788960"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.09.040191.002325"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi00184a014"},{"key":"e_1_2_6_43_1","volume-title":"Molecular Cloning. A Laboratory Manual","author":"Sambrook J.","year":"2001"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0952-7915(99)00015-1"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M202069200"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509049758"},{"key":"e_1_2_6_47_1","first-page":"4586","article-title":"Phase I trial of 2B1, a bispecific monoclonal antibody targeting c\u2010erbB\u20102 and Fc\u03b3RIII","volume":"55","author":"Weiner L.M.","year":"1995","journal-title":"Cancer Research"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050264"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.013"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.49.5.511"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2005.05414.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2005.05414.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T02:36:09Z","timestamp":1697423769000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2005.05414.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,13]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1111\/j.1365-2141.2005.05414.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05414.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,13]]},"assertion":[{"value":"2005-06-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}